About Valink Therapeutics

Valink creates next generation antibody-drug conjugates (ADCs) designed to treat cancers that current therapies cannot reach. Using its proprietary LiliumX platform, the company engineers bispecific ADCs with novel gating approaches that target tumour cells more precisely, reducing harm to healthy tissue. The platform combines synthetic protein biology, high-throughput screening, and artificial intelligence to test tens of thousands of molecular combinations. This discovery engine powers Valink's oncology pipeline, addressing colorectal cancer, non-small cell lung cancer, and pan-cancer solid tumours.